Gemcitabine is widely used in the treatment of various cancers. This study aims to evaluate gemcitabine-associated adverse events (AEs) using the Food and Drug Administration Adverse Event Reporting S

Taylor & Francis Group2025-03-13 更新40

Toxicity profiles associated with EGFR-TKIs combined with angiogenesis inhibitors in non-small cell lung cancer: an epidemiological surveillance analysis of the FDA adverse event reporting system

毒性

药物警戒

Ongoing studies are evaluating the efficacy and toxicity profiles of combining epidermal growth factor receptor inhibitors (EGFR-TKIs) with antiangiogenic agents in non-small cell lung cancer (NSCLC).

Taylor & Francis Group2025-10-02 更新20

Drug-induced skin ulcer: real-world pharmacovigilance analysis based on the FDA adverse event reporting system

药物不良反应监测

药物警戒

Skin ulcer (SU) may increase the risk of systemic infections and have evolved into an important public health problem. However, there is a lack of research specifically on drug-induced SU. We extracte

Taylor & Francis Group2025-05-14 更新40

Incidence, causes, and consequences of preventable adverse drug reactions occurring in inpatients: A systematic review of systematic reviews

药物警戒

住院患者安全

Background Preventable adverse drug reactions (PADRs) in inpatients are associated with harm, including increased length of stay and potential loss of life, and result in elevated costs of care. We co

NIAID Data Ecosystem20

Signal strength of reports of finasteride administration in male at the PT level.

资源简介：

相关数据集